|
| | | | | | | | | | | |
| Name | Indication | MOA | Approval | Economics | Admin | IP | | Price | 3.4 | |
| Vtama (tapinarof) | Psoriasis, AD | | | JT, Torii | | | | Shares | 695.878859 | Q222 |
| | | | Phase | | | | | MC | 2365.9881206 | |
| brepocitinib | SLE, Dermatomyositis | TYK2/JAK1 | III | PFE | | | | Cash | 2257.756 | Q222 |
| batoclimab | TED, MG | FcRn | | | | | | Debt | 417.024 | Q222 |
| RVT-2001 | MDS | | | | | | | EV | 525.2561206000001 | |
| namilumab | Sarcoidosis | | | | | | | | | |
| | | | | | | | | CEO: Matt Gline | | |
| | | | | | | | | CCO: Amy Mahery | | |
| | | | | | | | | | | |
| | | | | | | | | QVT | 129 | |
| Affivant | AFVT-2101 | | | | | | | Softbank | 99 | |
| Arbitus | ARU-2801?, ARU-1801? | | | | | | | Viking | 88 | |
| Datavant | | | | | | | | Dexcell | 99 | |
| Dermavant | | | | | | | | Sumitomo | 86 | |
| Genevant | | | | | | | | Vivek | 78 | |
| Hemavant | | | | | | | | | 579 | |
| Immunovant | | | | 8/30/22: Investor conferences | | | | | | |
| Kinevant | | | | | | | | | | |
| Lokavant | LSVT-1701? | | | | | | | | | |
| Priovant | brepocitinib, ropsacitinib | PFE owns 25% | | | | | | | | |
| Proteovant | | | | | | | | | | |
| Silicon Therapeutics - $450m!? | | | | | | | | | | |
| VantAI | | | | | | | | | | |